Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics, Inc. develops, manufactures and sells medical technology devices used by professional healthcare providers in vascular disease, oncology and surgical settings. The company’s recurring updates center on its Med Tech portfolio, including AlphaVac and AngioVac mechanical thrombectomy products, Auryon, and the NanoKnife System for irreversible electroporation-based tumor ablation.
Company news also covers fiscal earnings, guidance changes, product adoption, reimbursement and coding topics, FDA clearances and investigational device exemptions, and expanded European indications for NanoKnife across liver, pancreas, kidney and prostate tumors. Other recurring items include pulmonary embolism research initiatives, cardiovascular scientific forums, investor conference presentations and portfolio changes following completed divestitures and discontinued product lines.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
AngioDynamics, Inc. (NASDAQ: ANGO) has announced that President and CEO Jim Clemmer, along with Executive VP and CFO Stephen Trowbridge, will present at the Needham 22nd Annual Virtual Healthcare Conference on April 17, 2023, at 8:00 a.m. ET. The presentation aims to showcase the company’s innovative medical technologies focused on enhancing blood flow and cancer treatment options, ultimately improving patient quality of life.
A live webcast will be available in the “Investors” section of AngioDynamics’ website, with a replay accessible post-event. The presentation highlights the company’s commitment to addressing unmet patient needs through its transformative medical solutions.
AngioDynamics reported third-quarter fiscal 2023 net sales of $80.7 million, a 9.1% increase from last year. Med Tech sales grew 16.6% to $22.9 million, driven by Auryon and NanoKnife products. However, gross margin decreased to 50.2%, down 200 basis points year-over-year. The company reported a net loss of $9.5 million or $0.24 per share, compared to a loss of $5.0 million a year ago. Adjusted EBITDA was $4.3 million, falling from $6.7 million in Q3 2022. Due to lower AngioVac sales, the fiscal 2023 guidance for net sales was revised downward to $338 million to $342 million.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for Q3 of fiscal year 2023 on March 30, 2023, before the market opens. A conference call is scheduled for 8:00 a.m. ET that same day to discuss the results. Interested participants can call 1-877-407-0784 (domestic) or +1-201-689-8560 (international) using passcode 13737051. The call will also be available via webcast on the AngioDynamics website, with a replay accessible beginning at 11:00 a.m. ET on the same day until April 6, 2023.